SMARCA2 and cancer: Mutations in the BRG1 gene lead to increased reliance on the ATPase activity of BRM for cancer cell growth due to its partial compensation for the functional deficiency of BRG1, this discovery unveils a synthetic lethal relationship between BRM and BRG1, positioning BRM as an attractive anti‐cancer target [67].